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ABSTRACT  
Pre-eclampsia is a pregnancy disorder of unknown origin. In Norway, pre-eclampsia is reported in 3 to 4 per 
cent of registered births. At present, November 2014, a series of investigations into the etiology of pre-
eclampsia have been published internationally from the Norwegian Mother and Child Cohort Study (MoBa), 
and several studies are ongoing. The intention of this paper is to give a short summary of what has been 
accomplished, and to discuss future avenues of research concerning causes, mechanisms and consequences 
of pre-eclampsia. The papers that have been published up to now include seven that concern life-styles 
(physical activity, tobacco and diet), six that include prior pregnancies, infection, gestational weight gain, 
toxicants and tryptophan metabolism, and two studies concerning issues of selection and validity. Major 
findings are that tobacco smoking is only associated with reduced risk of pre-eclampsia when it occurs in the 
last trimester; that processed food and sugar-sweetened beverages are associated with increased risk while 
vegetables, vitamin D and probiotics are associated with reduced risk; and that prior induced abortions have 
the same risk-reducing effect as a prior pregnancy. For future studies, we suggest that better use should be 
made of the family structure built into MoBa. This includes better use of the discordant pregnancy design. A 
series of ongoing genetic studies, partly in international consortia, will hopefully open new etiological 
insights. The indications that pre-eclampsia is related to cardiovascular disease and other complex disorders 
should be further investigated through systematic follow-up of pre-eclamptic women and controls. Finally, 
MoBa is eminently suited to study the influences that pre-eclampsia can have on the growing child. 
 
This is an open access article distributed under the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
 
 
INTRODUCTION 
 
Pre-eclampsia is an ill-defined disease with unknown 
etiology that each year causes a large number of ma-
ternal and fetal deaths worldwide, as well as long-term 
disabilities in children born prematurely [1]. In socie-
ties without sufficient antenatal care, the disease is 
sometimes not recognized until the occurrence of the 
dramatic convulsions of eclampsia. Eclampsia is a life-
threatening condition characterized by cerebral edema 
and liver failure. Fortunately, in societies with suffici-
ent antenatal care, blood pressure is taken and any 
presence of elevated levels of protein in the urine is 
recorded at regular visits, which means that early signs 
of disease can be detected and sometimes treated. The 
only real cure is the delivery of the placenta, but other 
remedies have been recommended to reduce symptoms 
such as antihypertensive medication and tranquilizers. 
Many randomized, controlled trials have been per-
formed without much success. At present, aspirin is 
recommended and believed to act through anti-
inflammatory mechanisms [2]. 
 The reason that pre-eclampsia can be characterized 
as ill-defined, lies in the fact that the commonly em-
ployed criteria for setting the diagnosis are elevated 
blood pressure after week 20 combined with protein-
uria. But both blood pressure and protein levels fluctu-
ate, and it is probable that many cases, especially those 
occurring in the last part of pregnancy, go undetected, 
since hypertension and proteinuria may not be present 
at the same antenatal visit. Some investigators have 
proposed that pre-eclampsia is only the tip of the 
iceberg, i.e. that pregnancy represents a heightened 
state of inflammation that can vary from person to 
person [3]. For each woman, the presence of overt dis-
ease will depend on the length of gestation as well as 
characteristics such as body mass index (BMI), parity, 
prior pregnancy outcomes, diabetes and multifetal 
pregnancy, to name a few that are considered well-
established risk factors for pre-eclampsia. The hetero-
geneous nature of the disorder has led to some pessi-
mism as to the possibility to find etiological factors 
with large effects. 
 Genetic factors have long been suspected of being 
responsible for at least part of the etiology, based on 
familial aggregation and twin studies. To what extent 
maternal, fetal or maternal-fetal genetic interaction is 
responsible is not clear. As yet, no genes have been 
replicated with sufficient statistical significance. A 
large number of biomarkers have been associated with 
pre-eclampsia, but there is not yet any established 
predictive model based on data from the first half of 
pregnancy that can be used clinically with any great 
precision. Some of these associated biomarkers may 
point us towards genes or environmental exposures of 
etiological significance, but many of them are pre-
sumably only downstream consequences of the many 
metabolic alterations induced by pre-eclampsia. 
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 The intention of this paper is to give an overview of 
the scientific activity in the Norwegian Mother and 
Child Cohort Study (MoBa) as it relates to investiga-
tions of pre-eclampsia, and to discuss future avenues 
of research. MoBa is a large pregnancy cohort with a 
built-in family design. The cohort is described in detail 
in preceding papers in this issue, and information is 
also available on www.fhi.no/moba. 
 
 
MOBA PUBLICATIONS 
 
Smoking  
One of the enigmas in pre-eclampsia research has been 
the negative association to smoking. It has repeatedly 
been found that women who smoke have a lower risk 
of developing the disease. In order to understand the 
biological mechanisms behind this observation, 
Stephanie M. Engel from the University of North Ca-
rolina received a grant from the National Institutes of 
Health in the US. The aim has been to use DNA from 
case and control dyads (mother and child) in MoBa to 
genotype polymorphic genetic markers (single nucleo-
tide polymorphisms – SNPs) in metabolic pathways in 
which tobacco might have an influence. The aims have 
now been extended to include the complete genome, in 
a GWAS study. If the genetic analyses can point to 
new genes that reveal important pathophysiological 
mechanisms, it may lead to the development of better 
therapies. As part of this project, an association study 
between smoking and pre-eclampsia was performed. 
Exposure to tobacco was based on responses to two 
questionnaires, sent to the pregnant women in gestatio-
nal weeks 15 to 17 and week 30, while the information 
on pre-eclampsia was derived from the birth record in 
the Medical Birth Registry of Norway. It was found 
that, whereas 23% of the pregnant women reported 
smoking in the first trimester, only 9 and 8% smoked 
in the second and third trimester, respectively [4]. The 
main finding was that the risk of pre-eclampsia was 
only reduced for women who continued to smoke in 
the third trimester (adjusted OR = 0.57, 95% CI: 0.46-
0.70). Women who quit smoking before the last tri-
mester had about the same risk as non-smokers. No 
effect of passive smoking could be found. Thus, this 
observation confirms earlier reports of the apparent 
protective effect of smoking, but limits the effect to 
smoking in the last trimester. 
 
Nutrition  
There is a large interest in the effects of nutritional 
factors on the risk of pre-eclampsia. In MoBa, a semi-
quantitative food frequency questionnaire has been 
developed [5]. An impressive number of publications, 
more than 50, have been published up to now, based 
on dietary data. In an accompanying paper, Brantsæter 
et al. gives a summary of the methodology and the 
results of the investigations, including a discussion of 
the strengths and limitations of nutritional studies 
during pregnancy [6]. 
 A previous study that reported reduced levels in 
early pregnancy of serum 25-hydroxyvitamin D for wo-
men who later developed pre-eclampsia [7], prompted 
a study of the relationship between vitamin D supple-
mentation and pre-eclampsia. It was found that the 
relative risk of pre-eclampsia for women with a total 
vitamin D intake of 15-20 grams per day compared to 
less than 5 grams per day was 0.76 (95% CI: 0.60-
0.95) [8]. No effect of dietary vitamin D alone was 
found. This protective effect is in line with other re-
ports, although it has recently been concluded that the 
quality of evidence is insufficient to determine a causal 
association between vitamin D and pre-eclampsia [9]. 
 Another fascinating observation in MoBa, as regards 
nutrition and pre-eclampsia, is the finding that intake 
of probiotic foods appears to reduce the risk of pre-
eclampsia. Probiotics are defined as live microorga-
nisms, which, when administered in adequate amounts, 
confer a health benefit on the host [10]. Recent years 
have witnessed an increasing interest in the effects that 
the bacterial composition in the intestines may have on 
diseases where inflammation and immunological res-
ponses are important. Pregnancy is a condition where 
many immunological functions undergo changes, and 
pre-eclampsia is considered to be a state of increased 
inflammation. The association between intake of pro-
biotics and pre-eclampsia in primiparous women was 
examined, and it was found that daily intake appeared 
to reduce the risk (OR = 0.80, 95% CI: 0.66-0.96) 
[11]. 
  Intake of dietary sugar has previously been found to 
increase the risk of pre-eclampsia in Norway [12]. 
Using MoBa data, it was found that added sugar in the 
diet was not associated with pre-eclampsia [13]. How-
ever, intake of more than 125 ml of sugar-sweetened 
beverages per day compared to no intake, was associa-
ted with increased pre-eclampsia risk (OR = 1.27, 95% 
CI: 1.05-1.27). In the discussion, the authors speculate 
that the association to sweet drinks is unlikely to be 
due to the added sugar. They also report that higher 
intakes of fresh and dried fruits were associated with 
reduced risk of pre-eclampsia. 
 Instead of studying effects of single nutrients or 
foods, the questionnaire also opens for the study of 
effects of dietary patters. Using principal component 
analysis, Brantsæter et al (14) showed that four dietary 
patterns emerged with sufficiently high eigenvalues. 
These patterns were given the following names based 
on loadings to certain foods: Vegetable, processed 
food, potato and fish, and cakes and sweets. Subjects 
with high factor scores on vegetables had lowest risk 
of pre-eclampsia, while having high factor scores on 
processed food was associated with increased risk. 
Variability in factor scores for potato and fish and 
cakes and sweets had little influence on the occurrence 
of pre-eclampsia. 
 Health effects of organic foods have been little stu-
died, and particularly not in relation to pre-eclampsia. 
Torjusen and coworkers have recently compared intake 
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of organic foods among women in MoBa with and 
without pre-eclampsia [15]. The food frequency quest-
ionnaire included 6 questions on the use of organic 
foods. No association to pre-eclampsia was found for 
the consumption of organic fruit, cereals, milk/dairy 
products, eggs or meat, while higher intake of organic 
vegetables appeared to decrease the risk of pre-
eclampsia. Comparing subjects who said they con-
sumed organic vegetables often or mostly to subjects 
saying rarely/never or sometimes gives an OR of 0.75 
(95% CI: 0.60-0.95). The risk reduction associated 
with use of organic vegetables was observed in addi-
tion to the risk reduction associated with healthy diet 
including vegetables. 
 Recently, the concept of the New Nordic Diet (NND) 
has been put forward. A scoring system has been 
constructed for ten subscales, including such items as 
meal frequency, Nordic fruits, root vegetables, pota-
toes, cabbages, whole grain bread, and the like. For the 
purpose of studying pre-eclampsia, subjects were cate-
gorized into low, medium and high NND adherence 
[16]. When subjects with high adherence to NND were 
compared to subjects with low adherence, the OR for 
pre-eclampsia was 0.86 (95% CI: 0.78-0.95). In con-
trast to the other papers on nutrition, which only 
studied nulliparous women, this analysis included all 
women. 
 
Physical activity  
On the basis of analogies and associations between 
pre-eclampsia and cardiovascular disease, it has been 
suggested that regular physical activity during preg-
nancy can reduce the risk of pre-eclampsia. The first 
MoBa questionnaire asked how often the women 
performed 14 different leisure time physical activities, 
ranging from brisk walking to high-impact aerobic 
classes. A dose-response relationship was found, with 
a reduction in the occurrence of pre-eclampsia as the 
level of physical activity increased (17). For subjects 
with more than 25 activities per week the relative risk 
compared to subjects with no activities was OR = 0.79 
(95% CI: 0.65-0.96). However, no benefit was found 
for women with pre-pregnancy body mass index 
(BMI) above 30. 
 
Pre-pregnancy BMI and weight gain in pregnancy  
Pre-pregnancy BMI above 30 is a well-known risk fac-
tor for the development of pre-eclampsia. The effect of 
a high increase in body weight during pregnancy is 
less well established. The US Institute of Medicine 
(IOM) and National Research Council has issued 
recommendations for gestational weight gain (GWG). 
In Norway, these guidelines have been adopted and the 
general advice is that normal weight women are 
recommended to increase 11.5-16 kg, while the advice 
for obese women is 5-9 kg. Haugen et al [18] set out to 
examine the risk of pre-eclampsia and other adverse 
pregnancy outcomes for women who fell outside these 
limits. For nulliparous women, the odds ratio for pre-
eclampsia was 2.44 (95% CI: 2.03-2.92) for women 
who had gained more weight than recommended. For 
parous women, the corresponding odds ratio was 2.19 
(95% CI: 1.62-2.96). When weight gain in pregnancy 
is associated with an outcome such as pre-eclampsia, 
reverse causation must be considered, since edema, a 
common consequence of pre-eclampsia, will cause 
increase in weight. 
 
Previous abortions and infertility  
The risk of pre-eclampsia is highest for women deli-
vering their first child. The causes and mechanisms 
behind this parity effect are not understood. We asked 
whether a first pregnancy that ended with abortion 
would lower the risk of pre-eclampsia in subsequent 
pregnancies. We found that having had two or more 
previous induced abortions had a strong effect on the 
later risk of pre-eclampsia, OR=0.36 (95% CI: 0.18-
0.73) [19]. One induced abortion had a smaller effect 
(OR = 0.87, 0.71-1.06). The effect after two or more 
abortions is similar to what is seen after one birth. In 
contrast, having had one or more miscarriages did not 
influence the risk of pre-eclampsia in a subsequent 
pregnancy. Infertility, recurrent miscarriages and pre-
eclampsia may share elements of the same etiological 
factors. When we looked at recurrent miscarriages 
(defined as three or more), an increased risk of pre-
eclampsia was found, although not statistically signifi-
cant (OR = 1.51, 95% CI: 0.80-2.83) [20]. Further-
more, having experienced infertility (defined as having 
received a treatment such as in vitro fertilization, 
operative or hormonal treatment), also had a certain 
risk-increasing influence (OR = 1.29, 95% CI: 1.05-
1.60). The combination of recurrent miscarriage and 
infertility treatment had a stronger effect on the risk of 
pre-eclampsia (OR = 2.40, 95% CI: 1.11-5.18). This 
finding is in agreement with a genetic theory, proposed 
by Ashley Moffett from Cambridge University, sugg-
esting that a certain combination of HLA-C alleles in 
the fetus interacts with haplotypes in the KIR gene in 
the mother. This can lead to reduced invasion of extra-
villous trophoblast cells in the decidua, and thereby 
cause infertility, spontaneous abortions, fetal growth 
restriction or pre-eclampsia [21]. The genetic details 
are elaborated in an accompanying paper in this issue 
[22]. 
 
Tryptophan metabolism  
Tryptophan is an essential amino acid. It is a precursor 
for serotonin. Tryptophan’s catabolic route is the 
kynurenine pathway. The activity in this pathway is 
influenced by immune responses and inflammatory 
mediators. Since inflammation is a characteristic of 
pre-eclampsia, it is of interest to compare the concen-
trations in plasma of metabolites in this pathway for 
women with and without pre-eclampsia. In a random 
subsample of 3000 MoBa participants, who gave birth 
in the period 2002-2003, the concentrations of trypto-
phan and six kynurenine pathway metabolites were 
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successfully measured in plasma samples, taken at 
week 17, for 2,936 women. 116 women developed 
pre-eclampsia. They had increased plasma levels of 
kynurenine acid (23.3 versus 20.7 nmol/l) [23]. An 
interaction with BMI was found. In women with BMI 
above 25, roughly 20% of women with level of 
kynurenine acid above the 95th percentile developed 
pre-eclampsia, compared to about 4% for women with 
BMI above 25 who had kynurenine levels in a refe-
rence category (between the 25th and 75th percentile). 
This result can aid in understanding the pathophysio-
logical processes in the development of pre-eclampsia, 
but it is not precise enough to be used as a predictive 
biomarker. 
 
Perfluoroalkyl substances  
Perfluoroalkyl substances (PFAS) are persistent envi-
ronmental contaminants, used in many consumer 
products such as surface treatments for carpets and 
fabrics. It is important to estimate whether PFAS and 
other contaminants can increase the risk of pre-
eclampsia and other adverse pregnancy outcomes. 
Mid-pregnancy plasma samples from about 500 
randomly selected cases of pre-eclampsia and 500 
controls were analyzed. The concentrations of a series 
of substances were measured. No significant risk-
increasing associations to pre-eclampsia were found. 
An inverse association between pre-eclampsia and the 
highest quartile of perfluoroundecanoic acid relative to 
the lowest quartile (relative risk 0.55, 95% CI: 0.31-
0.81) was reported [24]. If this inverse association is 
replicated by others, the mechanisms behind it should 
be studied further. 
 
Infection with cytomegalovirus  
Cytomegalovirus (CMV) usually infects early in life, 
but has a lifelong latent existence in the body. Primary 
infection or reactivation of the latent virus in preg-
nancy has been associated with severe outcomes, 
including fetal death. It is speculated that the infection 
may interfere with placentation, which can predispose 
for pre-eclampsia. Mid-pregnancy plasma samples 
from about 1500 pre-eclamptic women and 1000 con-
trols in MoBa were analyzed with respect to antibody 
status (IgG and IgM). Adjusted for maternal age, 
parity and smoking, the odds ratio for pre-eclampsia in 
women positive for CMV IgG was 0.89 (95% CI: 
0.74-1.05) [25]. In nulliparous women a slight, but 
statistically significant, protective effect of CMV was 
found. The results suggest that CMV infection is 
unlikely to be a major cause of pre-eclampsia. 
 
Validity and selection issues  
The record in the Medical Birth Registry of Norway 
(MBRN) is included as part of the MoBa database for 
each pregnancy. All pre-eclampsia projects use this 
diagnosis as the endpoint. All MoBa pregnancies re-
gistered with pre-eclampsia (n = 4081) and a randomly 
selected control group were subjected to further scru-
tiny. Hospital departments, where the births had taken 
place, were asked to provide copies of antenatal charts 
and hospital discharge codes. The antenatal charts 
include data on presence of increased urinary protein 
level and blood pressure measurements at the various 
pregnancy visits. Using this hospital-derived informa-
tion as the gold standard, the positive predictive value 
(PPV) of a pre-eclampsia diagnosis in MBRN was 
found to be 83.9% [26]. The PPV was higher for 
primiparous women. This result indicates that there is 
an element of misclassification of pre-eclampsia in 
papers that only use the MBRN diagnosis. To the 
extent that this is non-differential with respect to other 
variables that are studied, it will tend to weaken the 
estimated association measures. 
 In order to estimate the degree of recruitment bias 
in MoBa, Nilsen et al. [27] estimated prevalences and 
associations between certain exposures and outcomes 
in two data sets from the MBRN. One was the MoBa 
data set and the other was composed of all births in the 
same period (years 2000 to 2006) in Norway. The 
prevalence of pre-eclampsia was 3.9% in MoBa, and 
4.0% in the total population, giving a relative fre-
quency of 0.98 (95% CI: 0.94-1.01). In addition, the 
association between pre-eclampsia and parity could be 
estimated in both data sets. In MoBa, the adjusted odds 
ratio for pre-eclampsia comparing parity 1 to parity 0 
was 0.46 (95% CI: 0.42-0.50), while it was 0.47 (95% 
CI: 0.45-0.49) in the total population. These figures 
are reassuring, and suggest that projects using pre-
eclampsia based on MoBa data will most likely not 
suffer from recruitment bias to any large extent. 
 
 
CONCLUSIONS AND FUTURE PROSPECTS 
 
A series of new associations between exposures and 
pre-eclampsia have now been published using MoBa 
data. The smoking association was well known, but the 
novel finding is that it is only smoking in the last tri-
mester that matters. The many associations to nutritio-
nal factors and dietary patterns require confirmation. 
The findings may lead to better advice and guidelines 
for pregnant women. The new information from 
studies of abortion and infertility points to biological 
mechanisms that must be pursued in further research. 
The strong association between parity and pre-
eclampsia, which is a universal finding, is a mystery 
that requires more detailed follow-up studies, focusing 
on immunological mechanisms [28]. 
 Pre-eclampsia is not a new disease. It has almost the 
same prevalence all over the world. This fact suggests 
that we are dealing with a disease that is not easily 
amended by external environmental factors. Pre-
eclampsia is perhaps a consequence of the relentless 
conflict of interest between the mother and the fetus 
[29]. The placenta is mainly of fetal origin. Paternally 
derived genes in fetal cells will provoke maternal 
responses. The interest of the fetus is to grow as large 
and mature as possible before birth in order to increase 
the chance of extra-uterine survival. There is a limit to 
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maternal adaptation to this demand, if the mother is to 
retain her own good health. Thus, there are genes that 
need to be present for the good health of both orga-
nisms. Imprinting is a mechanism that can silence 
either paternally or maternally derived genes in the 
growing organism, and should be studied more closely 
for the development or avoidance of pre-eclampsia. If 
MoBa can contribute to finding the genes that are 
associated with pre-eclampsia, we can close in on the 
biological pathways leading to the disease. Genetic 
studies must analyze fetal and maternal genes simulta-
neously in order to grasp interaction effects. Two large 
ongoing studies will, in coming years, publish their 
findings from genome-wide association analyses based 
on MoBa data. One is the study conducted by Engel as 
referred to earlier, and the other is an international 
consortium headed by Linda Morgan, as presented 
elsewhere in this issue [30]. 
 MoBa’s family design means that paternal, fetal and 
maternal genes can be studied at the same time, open-
ing for studies of maternal-fetal interactions as well as 
imprinting effects (a certain allele will only have effect 
when it comes from one of the parents). In addition, 
many MoBa mothers have participated with more than 
one pregnancy. Women who have had pre-eclampsia 
in one but not another pregnancy (discordant pregnan-
cies) are of special interest, since the maternal genome 
is constant, but the fetal genome and environmental 
influences differ. 
 The heterogeneous nature of pre-eclampsia must be 
better understood. The heterogeneity is partly a pheno-
menon of degree of severity and partly of timing of 
events. The current dogma suggests that early pre-
eclampsia is related to poor placental blood perfusion 
due to lack of widening of the maternal spiral arteries. 
And it is suggested that signals and substances from 
the compromised placenta will, in predisposed women, 
lead to the maternal signs of diseases: endothelial 
damage, increased blood pressure, proteinuria, edema 
and inflammatory responses in many organs. However, 
for late onset pre-eclampsia, after 37 weeks of gesta-
tion, which constitutes about 60% of cases, normal 
placental perfusion is commonly found. Thus, pre-
eclampsia may have two subtypes, and only one of 
them is associated with poor placentation. Stratified 
analyses by type of pre-eclampsia should be 
considered in order to understand the etiology better. 
 The scientific challenges surrounding pre-
eclampsia are plentiful, and include not only questions 
on etiology and heterogeneity. We need better insight 
into pathophysiological mechanisms. The kynurenine 
finding described above can be helpful in this respect. 
We also need to find biomarkers and other characteris-
tics during pregnancy that can predict the development 
of the disease. That will help clinical management. 
Another line of research is related to the consequences 
of pre-eclampsia for the mother. There is now a large 
interest in the association between pre-eclampsia and 
later cardiovascular disease in the mother. As women 
with and without pre-eclampsia are followed up, 
MoBa will assemble data that can shed light on this 
association. Children exposed to pre-eclampsia in 
utero should also be followed closely to detect any 
long-term consequences. MoBa will continue to pro-
vide data that will help resolve causes, mechanisms 
and consequences of pre-eclampsia. 
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